Loading stock data…
Alpha Tau Medical Ltd (DRTS)
$14.84-0.19 (-1.26%)
Market ClosedLast close Sep 8
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Tau Medical Ltd. in the Healthcare sector is trading at $14.84 with a market capitalization of $840M. Wall Street consensus targets $17.80 (5 analysts), implying a +19.9% move over the next 12 months. The stock is currently near its 52-week high of $15.17, remaining 67.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.31M↓ | -$12.60M↓ | -$10.73M↓ | -$9.65M↓ | -$9.31M |
| Net Income | -$22.94M↓ | -$12.14M↓ | -$11.69M↓ | -$10.11M↓ | -$8.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$840.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-82.01%
Volume
Today's trading volume
561,445
Recent News
Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial
In July 2026, Alpha Tau Medical reported positive podium-presented data from a single-center trial showing that its Alpha DaRT device combined with pembrolizumab achieved a 100% objective response rate and encouraging survival outcomes in elderly patients with advanced head and neck squamous cell carcinoma, with only mild device-related side effects observed. A particularly interesting element is that the trial’s Simon two-stage adaptive design allowed enrollment to stop early for success...
New Strong Sell Stocks for July 7th
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
New Strong Sell Stocks for July 2nd
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform
Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient in Israel, marking the first intracranial application of its brain-specific delivery system outside the United States at Hadassah University Medical Center. This procedure not only extends Alpha DaRT’s reach into one of the most aggressive adult brain cancers, but also highlights the versatility of its minimally invasive, neuronavigation-guided platform across multiple...
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
Alpha Tau signed an agreement with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.